164 related articles for article (PubMed ID: 33080066)
1. Warfarin dosing algorithms: A systematic review.
Asiimwe IG; Zhang EJ; Osanlou R; Jorgensen AL; Pirmohamed M
Br J Clin Pharmacol; 2021 Apr; 87(4):1717-1729. PubMed ID: 33080066
[TBL] [Abstract][Full Text] [Related]
2. Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients.
Cho SM; Lee KY; Choi JR; Lee KA
Yonsei Med J; 2016 May; 57(3):635-40. PubMed ID: 26996562
[TBL] [Abstract][Full Text] [Related]
3. Implementing Algorithm-Guided Warfarin Dosing in an Ethnically Diverse Patient Population Using Electronic Health Records and Preemptive CYP2C9 and VKORC1 Genetic Testing.
Obeng AO; Kaszemacher T; Abul-Husn NS; Gottesman O; Vega A; Waite E; Myers K; Cho J; Bottinger EP; Ellis SB; Scott SA
Clin Pharmacol Ther; 2016 Nov; 100(5):427-430. PubMed ID: 27393744
[TBL] [Abstract][Full Text] [Related]
4. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
Takeuchi M; Kobayashi T; Brandão LR; Ito S
Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
[TBL] [Abstract][Full Text] [Related]
5. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
[TBL] [Abstract][Full Text] [Related]
6. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
7. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
8. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
[TBL] [Abstract][Full Text] [Related]
9. Development of a pharmacogenetic-based warfarin dosing algorithm and its performance in Brazilian patients: highlighting the importance of population-specific calibration.
Santos PC; Marcatto LR; Duarte NE; Gadi Soares RA; Cassaro Strunz CM; Scanavacca M; Krieger JE; Pereira AC
Pharmacogenomics; 2015 Jul; 16(8):865-76. PubMed ID: 26050796
[TBL] [Abstract][Full Text] [Related]
10. Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy.
Shaw K; Amstutz U; Kim RB; Lesko LJ; Turgeon J; Michaud V; Hwang S; Ito S; Ross C; Carleton BC;
Ther Drug Monit; 2015 Aug; 37(4):428-36. PubMed ID: 26186657
[TBL] [Abstract][Full Text] [Related]
11. Genotype-guided coumarin dosing: where are we now and where do we need to go next?
Baranova EV; Verhoef TI; Asselbergs FW; de Boer A; Maitland-van der Zee AH
Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):509-22. PubMed ID: 25595525
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups.
Dietz N; Ruff C; Giugliano RP; Mercuri MF; Antman EM
Int J Cardiol; 2020 Oct; 317():159-166. PubMed ID: 32505370
[TBL] [Abstract][Full Text] [Related]
13. Genotype-guided vs clinical dosing of warfarin and its analogues: meta-analysis of randomized clinical trials.
Stergiopoulos K; Brown DL
JAMA Intern Med; 2014 Aug; 174(8):1330-8. PubMed ID: 24935087
[TBL] [Abstract][Full Text] [Related]
14. CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients.
Panchenko E; Kropacheva E; Dobrovolsky A; Titaeva E; Zemlyanskaya O; Trofimov D; Galkina I; Lifshits G; Vereina N; Sinitsin S; Vorobyeva N; Grehova L; Zateyshchikov D; Zotova I; Vavilova T; Sirotkina O; Grontkovskaya A
Pharmacogenomics J; 2020 Oct; 20(5):687-694. PubMed ID: 32024944
[TBL] [Abstract][Full Text] [Related]
15. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.
Pathare A; Al Khabori M; Alkindi S; Al Zadjali S; Misquith R; Khan H; Lapoumeroulie C; Paldi A; Krishnamoorthy R
J Hum Genet; 2012 Oct; 57(10):665-9. PubMed ID: 22854539
[TBL] [Abstract][Full Text] [Related]
16. Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects.
Kadian-Dodov DL; van der Zee SA; Scott SA; Peter I; Martis S; Doheny DO; Rothlauf EB; Lubitz SA; Desnick RJ; Halperin JL
Vasc Med; 2013 Oct; 18(5):290-7. PubMed ID: 24029542
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Genotype-Guided Warfarin Dosing in the Chinese Population: A Meta-analysis of Randomized Controlled Trials.
Wang F; Guo J; Zhang A
J Cardiovasc Pharmacol; 2019 Mar; 73(3):127-135. PubMed ID: 30688796
[TBL] [Abstract][Full Text] [Related]
18. Effect of genetic and patient factors on warfarin pharmacodynamics following warfarin withdrawal: Implications for patients undergoing surgery.
Abohelaika S; Wynne H; Avery P; Kampouraki E; Kamali F
Thromb Res; 2018 Nov; 171():167-170. PubMed ID: 30321703
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
20. Prediction of sensitivity to warfarin based on VKORC1 and CYP2C9 polymorphisms in patients from different places in Colombia.
Cifuentes RA; Murillo-Rojas J; Avella-Vargas E
Biomedica; 2016 Mar; 36(1):91-100. PubMed ID: 27622442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]